Regular paper
Effects of antidepressant drugs on different receptors in the brain

https://doi.org/10.1016/0014-2999(81)90172-2Get rights and content

Abstract

Radioligand receptor binding techniques were used to characterize the effects of different structural types of antidepressant drugs on neurotransmitter receptors. The tricyclic antidepressants more or less potently inhibited the binding to rat brain preparations of several different radiolabelled ligands ([3H]WB4101, [3H]QNB, [3H]-d-LSD, [3H]mepyramine). The potency of the nontricyclic antidepressants varied greatly. Mianserin, potently displaced [3H]mepyramine, [3H]d-LSD and [3H]WB4101 while it was very weak on [3H]QNB-binding. Nomifensine and the specific 5-HT uptake inhibitors zimelidine and alaproclate had very low affinity for these receptors. All the antidepressants tested were practically devoid of activity on [3H]DHA binding, [3H]spiroperidol binding, [3H]flunitrazepam binding, [3H]muscimol binding and [3H]naloxone binding. The implications of these findings for biogenic amine theories of affective disorders are discussed.

References (76)

  • S. Montgomery et al.

    A double blind comparison of antidepressant efficacy of zimelidine, a new 5-HT uptake inhibitor, with amitriptyline

  • S.O. Ögren et al.

    Studies on the stereoselective dopamine receptor blockade in the rat brain by rigid spiroamines

    Life Sci.

    (1978)
  • S.J. Peroutka et al.

    Neuroleptic drug interactions with norepinephrine α-receptor binding sites in rat brain

    Neuropharmacology

    (1977)
  • R. Raisman et al.

    High-affinity [3H]imipramine binding in rat cerebral cortex

    European J. Pharmacol.

    (1979)
  • S.B. Ross et al.

    Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue

    European J. Pharmacol.

    (1969)
  • S.B. Ross et al.

    Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z)- and (E)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues

    Neuropharmacology

    (1977)
  • S.B. Ross et al.

    A comparison of the inhibitory activities of iprindole and imipramine on the uptake of 5-hydroxytryptamine and noradrenaline in brain slices

    Life Sci.

    (1971)
  • K. Sarai et al.

    Desmethylimipramine-induced decrease in β-adrenergic receptor binding in rat cerebral cortex

    Biochem. Pharmacol.

    (1978)
  • T. Segawa et al.

    Modifications of central 5-hydroxytryptamine binding sites in synaptic membranes from rat brain after longterm administration of tricyclic antidepresants

    European J. Pharmacol.

    (1979)
  • R. Simantov et al.

    The opiate receptor binding interactions of [3H]-methionine enkephalin, an opioid peptide

    European J. Pharmacol.

    (1978)
  • R.C. Speth et al.

    Benzodiazepine binding in human brain: characterization using [3H]flunitrazepam

    Life Sci.

    (1978)
  • F. Sulser et al.

    Mode of action of antidepressant drugs

    Biochem. Pharmacol.

    (1978)
  • D.C. U'Prichard et al.

    Distinct α-noradrenergic receptors differentiated by binding and physiological relationships

    Life Sci.

    (1979)
  • B.H.C. Westerink et al.

    On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs

    European J. Pharmacol.

    (1977)
  • G.K. Aghajanian et al.

    Physiology and pharmacology of central serotonergic neurons

  • S.P. Banerjee et al.

    Development of β-adrenergic receptor subsensitivity by antidepressants

    Nature

    (1977)
  • P.A. Baumann et al.

    Blockade of presynaptic α-receptors and of amine uptake in the rat brain by the antidepressant mianserine

    Naunyn-Schmiedeb. Arch. Pharmacol.

    (1977)
  • J.P. Bennett et al.

    d-LSD-binding to brain homogenates: possible relationship to serotonin receptors

    Life Sci.

    (1975)
  • J.P. Bennett et al.

    Serotonin and lysergic acid diethylamide binding in rat brain membranes: Relationship to postsynaptic serotonin receptors

    Mol. Pharmacol.

    (1976)
  • W.K. Bunney et al.

    Norepinephrine in depressive reactions

    Arch. Gen. Psychiat.

    (1965)
  • D.R. Burt et al.

    Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes

    Mol. Phramacol.

    (1976)
  • D.B. Bylund et al.

    β-Adrenergic receptor binding in membrane preparations from mammalian brain

    Mol. Pharmacol.

    (1976)
  • A. Carlsson et al.

    Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons

    Acta Physiol. Scand.

    (1966)
  • A. Coppen

    The biochemistry of affective disorders

    Br. J. Psychiat.

    (1967)
  • A. Coppen et al.

    Inhibition of 5-hydroxytryptamine reuptake by amitriptyline and zimelidine and its relationship to their therapeutic action

    Psychopharmacology

    (1979)
  • A. Coppen et al.

    Zimelidine: a therapeutic and pharmacokinetic study in depression

    Psychopharmacology

    (1979)
  • C. De Montigny et al.

    Tricyclic antidepressants: Long-term treatment increases responsitivity of rat brain fore-brain neurons to serotonin

    Science

    (1978)
  • G.M.B. Fillion et al.

    High-affinity binding of [3H]5-hydroxytryptamine to brain synaptosomal membranes: Comparison with [3H]lysergic acid diethylamide binding

    Mol. Pharmacol.

    (1978)
  • Cited by (296)

    • Compound action potential inhibition produced by various antidepressants in the frog sciatic nerve

      2018, European Journal of Pharmacology
      Citation Excerpt :

      The adjuvants inhibit the pain through various mechanisms. For example, mechanisms for the antinociception produced by antidepressants are (1) activation of the noradrenaline- and serotonin-containing descending antinociceptive pathway to spinal dorsal horn by inhibiting the reuptake of their neurotransmitters (Ardid et al., 1995; Max et al., 1992), (2) involvement of α adrenoceptors, H1-histamine, serotonin, opioid and muscarinic acetylcholine receptors (Anjaneyulu and Chopra, 2006; Cervantes-Durán et al., 2013; Ghelardini et al., 2000; Hall and Ögren, 1981; O’Donnell and Shelton, 2011; Sindrup et al., 2005; Wong and Bymaster, 2002) and (3) inhibition of voltage-gated Na+ (Dick et al., 2007; Ishii and Sumi, 1992; Le Cudennec and Castagné, 2014; Leffler et al., 2007; Nicholson et al., 2002; Pancrazio et al., 1998; Song et al., 2000; Stoetzer et al., 2016; Wang et al., 2004, 2010; Yan et al., 2010), Ca2+ (Traboulsie et al., 2006; Wu et al., 2012), NMDA-receptor (Reynolds and Miller, 1988; Sernagor et al., 1989; Watanabe et al., 1993) and P2X4-receptor channels (Nagata et al., 2009). The Na+-channel inhibition is mimicked by antiepileptics, α2-adrenoceptor agonists and local anesthetics, and therefore is one of mechanisms for antinociception produced by the other adjuvants.

    • Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders

      2015, European Neuropsychopharmacology
      Citation Excerpt :

      Clomipramine (FDA approved, 1964) was found to be more selective in blocking 5-HT re-uptake compared to previously-launched TCAs (Carlsson et al., 1969; Millan et al., 2001). Interestingly, clomipramine is also effective in the treatment of panic disorder and especially obsessive compulsive disorder (OCD), by a mechanism poorly understood even today (Fineberg and Gale, 2005; Hall and Ogren, 1981; Pizarro et al., 2014). The above-mentioned premise that an elevation in 5-HT availability enhances mood set the stage for the intensive search for 5-HT selective reuptake inhibitors (SSRIs) in the 1970s and 1980s by almost every major pharmaceutical firm worldwide (Block and Nemeroff, 2014; Connolly and Thase, 2012; Healy, 1997).

    • Analgesic effects of antidepressants alone and after their local co-administration with morphine in a rat model of neuropathic pain

      2014, Pharmacological Reports
      Citation Excerpt :

      A question regarding the involvement of the opioid system after local administration of antidepressants still remains unclear. Initial investigations suggested that tricyclic antidepressants have a low affinity to opioid receptors [55]. Venlafaxine has been characterized as being able to act on the opioid system and enhance opioid analgesia when administered with a selective opioid agonist, and this action is inhibited by selective opioid antagonists. [56].

    • Antidepressants

      2009, Current Therapy in Pain
    View all citing articles on Scopus
    View full text